Opus Genetics (NASDAQ:IRD) Given “Buy” Rating at BTIG Research

Opus Genetics (NASDAQ:IRD)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a report issued on Wednesday, Benzinga reports. They currently have a $12.00 price objective on the stock. BTIG Research’s target price would suggest a potential upside of 119.14% from the company’s previous close.

IRD has been the subject of several other research reports. Guggenheim initiated coverage on Opus Genetics in a research report on Thursday, June 4th. They issued a “buy” rating and a $16.00 price target for the company. Wall Street Zen raised Opus Genetics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Zacks Research upgraded Opus Genetics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Chardan Capital reissued a “buy” rating and set a $13.00 target price on shares of Opus Genetics in a research report on Wednesday. Finally, Royal Bank Of Canada cut their target price on Opus Genetics from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.69.

Opus Genetics Stock Up 26.2%

Opus Genetics stock traded up $1.14 during mid-day trading on Wednesday, reaching $5.48. 35,038,599 shares of the company’s stock traded hands, compared to its average volume of 1,168,929. The company has a market cap of $452.59 million, a price-to-earnings ratio of -4.04 and a beta of 0.58. The stock has a 50 day moving average of $3.79 and a two-hundred day moving average of $4.29. Opus Genetics has a 12-month low of $1.32 and a 12-month high of $7.07.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $2.63 million. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. As a group, sell-side analysts forecast that Opus Genetics will post -0.99 earnings per share for the current year.

Insider Activity at Opus Genetics

In related news, CEO George Magrath sold 9,475 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The stock was sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the sale, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at approximately $5,109,013.55. This trade represents a 0.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Robert E. Gagnon sold 28,000 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $4.54, for a total value of $127,120.00. Following the transaction, the chief financial officer owned 556,375 shares of the company’s stock, valued at approximately $2,525,942.50. The trade was a 4.79% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 57,331 shares of company stock valued at $213,749 in the last 90 days. Company insiders own 11.70% of the company’s stock.

Institutional Trading of Opus Genetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Opus Genetics during the second quarter valued at $12,809,000. Nantahala Capital Management LLC bought a new stake in Opus Genetics during the 2nd quarter valued at about $12,582,185. Trails Edge Capital Partners LP bought a new stake in Opus Genetics during the 2nd quarter valued at about $11,276,434. Balyasny Asset Management L.P. purchased a new stake in Opus Genetics in the 4th quarter valued at about $5,463,000. Finally, Millennium Management LLC bought a new position in Opus Genetics in the 4th quarter worth about $4,025,000. Hedge funds and other institutional investors own 14.97% of the company’s stock.

Opus Genetics News Summary

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Promising OPGx-BEST1 results: In the low-dose first cohort of the Phase 1/2 BIRD-1 trial, all five participants showed clinically meaningful improvements in visual function. Three of five patients recorded meaningful best-corrected visual-acuity improvements, while retinal-sensitivity improvements were observed in three of four evaluable patients. No serious adverse events or dose-limiting toxicities were reported. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: FDA alignment improves development outlook: Following a Type C meeting, the FDA agreed that at least a three-decibel microperimetry improvement combined with patient-reported outcomes could serve as a potential pivotal-trial endpoint. Cohort 2 was over-enrolled, with dosing expected to finish in the fourth quarter of 2026 and initial three-month data anticipated in the second quarter of 2027. The company said its cash runway extends into 2029, potentially supporting multiple development milestones and possible priority-review-voucher opportunities. FDA Type C Meeting and Clinical Trial Update
• Positive Sentiment: Analyst support and options activity: Chardan Capital reaffirmed its “buy” rating and maintained a $13 price target, implying substantial upside from recent trading levels. Call-option purchases reached 4,820 contracts, about 681% above typical volume, reflecting heightened bullish speculation, although options activity can also increase volatility.
• Neutral Sentiment: Insider transaction: CFO Robert Gagnon sold 28,000 shares for approximately $127,120. The filing stated that the sale covered tax-withholding obligations tied to vested equity awards, reducing its bearish significance; he still held 556,375 shares afterward. Opus Genetics CFO Stock Sale

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.